Skip to main content
. 2017 Mar 23;6(4):768–777. doi: 10.1002/cam4.1049

Figure 4.

Figure 4

ADCC of chLpMab‐2 against hPDPN‐expressing cell lines. (A) ADCC of chLpMab‐2 using human MNCs against (A) LN319, PC‐10, and NCI‐H226 and (B) CHO and CHO/hPDPN were evaluated by a 6‐h 51Cr release assay in the presence of 1 μg/mL of antibody with an E/T ratio of 100. **< 0.01